Autolus Therapeutics (AUTL) Receivables - Other (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Receivables - Other for 9 consecutive years, with $915000.0 the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Other rose 86.35% year-over-year to $915000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $915000.0 (up 86.35% YoY) and the FY2025 annual result came in at $915000.0, down 35.61% from the prior year.
• Receivables - Other fell to $915000.0 in Q4 2025 per AUTL's latest filing, from $936000.0 in the prior quarter.
• Over the last five years, Receivables - Other for AUTL reached as high as $10.7 million in Q3 2021 and fell as low as $257000.0 in Q1 2021.
• A 5-year average of $1.4 million and a median of $700500.0 in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2021 — Receivables - Other surged 1249.37% — and 2022, when it plunged 97.46%.
• Year by year, Receivables - Other stood at $271000.0 in 2021, then jumped by 429.52% to $1.4 million in 2022, then tumbled by 64.04% to $516000.0 in 2023, then dropped by 4.84% to $491000.0 in 2024, then jumped by 86.35% to $915000.0 in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $915000.0, $936000.0, and $665000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.